Revising the definition of Alzheimer's disease: A new lexicon

Bruno Dubois; Howard H. Feldman; Claudia Jacova; Jeffrey L. Cummings; Steven T. DeKosky; Pascale Barberger-Gateau; André Delacourte; Giovanni Frisoni; Nick C. Fox; Douglas Galasko; Serge Gauthier; Harald Hampel; Gregory A. Jicha; Kenichi Meguro; John O'Brien; Florence Pasquier; Philippe Robert; Martin Rossor; Steven Salloway; Marie Sarazin; Leonardo C. de Souza; Yaakov Stern; Pieter J. Visser; Philip Scheltens

doi:10.1016/S1474-4422(10)70223-4

Revising the definition of Alzheimer's disease: A new lexicon

Bruno Dubois
, Howard H. Feldman
, Claudia Jacova
, Jeffrey L. Cummings
, Steven T. DeKosky
, Pascale Barberger-Gateau
, André Delacourte
, Giovanni Frisoni
, Nick C. Fox
, Douglas Galasko
, Serge Gauthier
, Harald Hampel
, Gregory A. Jicha
, Kenichi Meguro
, John O'Brien
, Florence Pasquier
, Philippe Robert
, Martin Rossor
, Steven Salloway
, Marie Sarazin

Leonardo C. de Souza, Yaakov Stern, Pieter J. Visser, Philip Scheltens

Research output: Contribution to journal › Review article › peer-review

1697 Citations (SciVal)

Abstract

Alzheimer's disease (AD) is classically defined as a dual clinicopathological entity. The recent advances in use of reliable biomarkers of AD that provide in-vivo evidence of the disease has stimulated the development of new research criteria that reconceptualise the diagnosis around both a specific pattern of cognitive changes and structural/biological evidence of Alzheimer's pathology. This new diagnostic framework has stimulated debate about the definition of AD and related conditions. The potential for drugs to intercede in the pathogenic cascade of the disease adds some urgency to this debate. This paper by the International Working Group for New Research Criteria for the Diagnosis of AD aims to advance the scientific discussion by providing broader diagnostic coverage of the AD clinical spectrum and by proposing a common lexicon as a point of reference for the clinical and research communities. The cornerstone of this lexicon is to consider AD solely as a clinical and symptomatic entity that encompasses both predementia and dementia phases.

Original language	English
Pages (from-to)	1118-1127
Number of pages	10
Journal	The Lancet Neurology
Volume	9
Issue number	11
DOIs	https://doi.org/10.1016/S1474-4422(10)70223-4
State	Published - Nov 2010

Bibliographical note

Funding Information:
The International Working Group received financial funding from Eisai France to support the meeting room cost for the ICAD 2009 meeting. The authors gratefully acknowledge discussion with Lon Schneider, University of Southern California, concerning the manuscript.

Funding

The International Working Group received financial funding from Eisai France to support the meeting room cost for the ICAD 2009 meeting. The authors gratefully acknowledge discussion with Lon Schneider, University of Southern California, concerning the manuscript.

Funders	Funder number
Eisai France
Medical Research Council	G0601846
Medical Research Council

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1016/S1474-4422(10)70223-4

Cite this

Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., Gauthier, S., Hampel, H., Jicha, G. A., Meguro, K., O'Brien, J., Pasquier, F., Robert, P., Rossor, M., Salloway, S., ... Scheltens, P. (2010). Revising the definition of Alzheimer's disease: A new lexicon. The Lancet Neurology, 9(11), 1118-1127. https://doi.org/10.1016/S1474-4422(10)70223-4

@article{41add742cb2b49f687fe91788f78891b,

title = "Revising the definition of Alzheimer's disease: A new lexicon",

abstract = "Alzheimer's disease (AD) is classically defined as a dual clinicopathological entity. The recent advances in use of reliable biomarkers of AD that provide in-vivo evidence of the disease has stimulated the development of new research criteria that reconceptualise the diagnosis around both a specific pattern of cognitive changes and structural/biological evidence of Alzheimer's pathology. This new diagnostic framework has stimulated debate about the definition of AD and related conditions. The potential for drugs to intercede in the pathogenic cascade of the disease adds some urgency to this debate. This paper by the International Working Group for New Research Criteria for the Diagnosis of AD aims to advance the scientific discussion by providing broader diagnostic coverage of the AD clinical spectrum and by proposing a common lexicon as a point of reference for the clinical and research communities. The cornerstone of this lexicon is to consider AD solely as a clinical and symptomatic entity that encompasses both predementia and dementia phases.",

author = "Bruno Dubois and Feldman, \{Howard H.\} and Claudia Jacova and Cummings, \{Jeffrey L.\} and DeKosky, \{Steven T.\} and Pascale Barberger-Gateau and Andr{\'e} Delacourte and Giovanni Frisoni and Fox, \{Nick C.\} and Douglas Galasko and Serge Gauthier and Harald Hampel and Jicha, \{Gregory A.\} and Kenichi Meguro and John O'Brien and Florence Pasquier and Philippe Robert and Martin Rossor and Steven Salloway and Marie Sarazin and \{de Souza\}, \{Leonardo C.\} and Yaakov Stern and Visser, \{Pieter J.\} and Philip Scheltens",

note = "Funding Information: The International Working Group received financial funding from Eisai France to support the meeting room cost for the ICAD 2009 meeting. The authors gratefully acknowledge discussion with Lon Schneider, University of Southern California, concerning the manuscript.",

year = "2010",

month = nov,

doi = "10.1016/S1474-4422(10)70223-4",

language = "English",

volume = "9",

pages = "1118--1127",

number = "11",

}

Dubois, B, Feldman, HH, Jacova, C, Cummings, JL, DeKosky, ST, Barberger-Gateau, P, Delacourte, A, Frisoni, G, Fox, NC, Galasko, D, Gauthier, S, Hampel, H, Jicha, GA, Meguro, K, O'Brien, J, Pasquier, F, Robert, P, Rossor, M, Salloway, S, Sarazin, M, de Souza, LC, Stern, Y, Visser, PJ & Scheltens, P 2010, 'Revising the definition of Alzheimer's disease: A new lexicon', The Lancet Neurology, vol. 9, no. 11, pp. 1118-1127. https://doi.org/10.1016/S1474-4422(10)70223-4

TY - JOUR

T1 - Revising the definition of Alzheimer's disease

T2 - A new lexicon

AU - Dubois, Bruno

AU - Feldman, Howard H.

AU - Jacova, Claudia

AU - Cummings, Jeffrey L.

AU - DeKosky, Steven T.

AU - Barberger-Gateau, Pascale

AU - Delacourte, André

AU - Frisoni, Giovanni

AU - Fox, Nick C.

AU - Galasko, Douglas

AU - Gauthier, Serge

AU - Hampel, Harald

AU - Jicha, Gregory A.

AU - Meguro, Kenichi

AU - O'Brien, John

AU - Pasquier, Florence

AU - Robert, Philippe

AU - Rossor, Martin

AU - Salloway, Steven

AU - Sarazin, Marie

AU - de Souza, Leonardo C.

AU - Stern, Yaakov

AU - Visser, Pieter J.

AU - Scheltens, Philip

N1 - Funding Information: The International Working Group received financial funding from Eisai France to support the meeting room cost for the ICAD 2009 meeting. The authors gratefully acknowledge discussion with Lon Schneider, University of Southern California, concerning the manuscript.

PY - 2010/11

Y1 - 2010/11

N2 - Alzheimer's disease (AD) is classically defined as a dual clinicopathological entity. The recent advances in use of reliable biomarkers of AD that provide in-vivo evidence of the disease has stimulated the development of new research criteria that reconceptualise the diagnosis around both a specific pattern of cognitive changes and structural/biological evidence of Alzheimer's pathology. This new diagnostic framework has stimulated debate about the definition of AD and related conditions. The potential for drugs to intercede in the pathogenic cascade of the disease adds some urgency to this debate. This paper by the International Working Group for New Research Criteria for the Diagnosis of AD aims to advance the scientific discussion by providing broader diagnostic coverage of the AD clinical spectrum and by proposing a common lexicon as a point of reference for the clinical and research communities. The cornerstone of this lexicon is to consider AD solely as a clinical and symptomatic entity that encompasses both predementia and dementia phases.

AB - Alzheimer's disease (AD) is classically defined as a dual clinicopathological entity. The recent advances in use of reliable biomarkers of AD that provide in-vivo evidence of the disease has stimulated the development of new research criteria that reconceptualise the diagnosis around both a specific pattern of cognitive changes and structural/biological evidence of Alzheimer's pathology. This new diagnostic framework has stimulated debate about the definition of AD and related conditions. The potential for drugs to intercede in the pathogenic cascade of the disease adds some urgency to this debate. This paper by the International Working Group for New Research Criteria for the Diagnosis of AD aims to advance the scientific discussion by providing broader diagnostic coverage of the AD clinical spectrum and by proposing a common lexicon as a point of reference for the clinical and research communities. The cornerstone of this lexicon is to consider AD solely as a clinical and symptomatic entity that encompasses both predementia and dementia phases.

UR - https://www.scopus.com/pages/publications/77957951112

UR - https://www.scopus.com/pages/publications/77957951112#tab=citedBy

U2 - 10.1016/S1474-4422(10)70223-4

DO - 10.1016/S1474-4422(10)70223-4

M3 - Review article

C2 - 20934914

AN - SCOPUS:77957951112

SN - 1474-4422

VL - 9

SP - 1118

EP - 1127

JO - The Lancet Neurology

JF - The Lancet Neurology

IS - 11

ER -

Revising the definition of Alzheimer's disease: A new lexicon

Abstract

Bibliographical note

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this